STK33基因在非小细胞肺癌中表达的临床研究

Clinical study on the expression of STK33 gene in patients with non-small cell lung cancer

背景与目的:STK33基因(丝氨酸/苏氨酸激酶基因33)为近年新发现的非癌基因,位于人类染色体11p15.3。11p15.3区域是与临床上多种疾病,包括多种肿瘤相关的基因富集区域。本研究检测STK33基因在人肺癌组织中的表达情况,旨在探讨STK33基因在肺癌发生、发展过程中的作用。方法:采用实时荧光定量PCR方法、Westernblot蛋白印迹法分别检测33例患者标本中STK33的mRNA和蛋白表达情况。其中非小细胞肺癌(NSCLC)24例、肺良性病变9例,同时肺癌病例又分为肺癌组、远癌组(距肿瘤活检切除边缘外3～6cm的组织)。最后我们把远癌组和肺良性病变统一划分为对照组。结果:实时荧光定量PCR方法检测STK33基因的表达情况,肺癌组织(△CT=8.7±2.0)高于远癌组织(△CT=9.7±1.4)及肺良性病变组织(△CT=10.5±0.9),差异具有统计学意义(P<0.05)。肺癌组织中STK33表达量与NSCLC患者的性别、年龄、吸烟史、肿瘤大小、组织学类型、分化程度、分期及患者淋巴结转移无关(P>0.05)。Westernblot蛋白印迹法检测STK33蛋白表达情况,肺癌组织的蛋白表达水平显著高于对照组组织。结论:肺癌组织中STK33的差异性表达与肺癌的发生、发展有一定联系。

Background and purpose：Serine threonine kinase 33 is a non-oncogene which was recently discovered in the course of sequencing the human chromosome region 11p15.3. Chromosome 11p15.3 is a gene- rich region which is of clinical importance because several human diseases have been mapped there. In this study, we analyzed the expression of STK33 in patients with non-small cell lung cancer （NSCLC） in order to identify the role of STK33 in the tumorigenesis and development of NSCLC. Methods：We evaluated STK33 mRNA and protein expression in NSCLC tissue samples from patients using real-time qPCR and Western blot. Thirty-three specimens from selected patients diagnosed at Kunhua Hospital from April to September of 2009 were enrolled in the study, including 24 lung cancer cases and 9 lung benign disease cases. The 24 lung cancer cases were then divided into a lung carcinoma group and a distal cancerous tissues group. Finally, we classified the distal cancerous tissues group and lung benign disease group as the control group. Results：The real-time qPCR study demonstrated that the level of STK33 mRNA in NSCLC （△CT=8.7±2.0） was significantly higher than the distal cancerous ones （△CT=9.7±1.4） or those in the lung benign disease group （△CT=10.5±0.9, P0.05）. STK33 expression was not associated with gender, age, smoking history, tumor size, histological type, differentiation degree, cancer stage, or lymph node metastasis in NSCLC patients（P0.05）.A significant difference was detected by Western blot, between the STK33 protein expression of NSCLC cases and control group cases. Conclusion：STK33 appears to play a central role in tumorigenesis and development of NSCLC.